---
title: "Shilpa Medicare Ltd (SHILPAMED) — Share Price, Financials & Analysis"
symbol: "SHILPAMED"
company: "Shilpa Medicare Ltd"
canonical: "https://tapetide.com/stocks/SHILPAMED"
isin: "INE790G01031"
nse_symbol: "SHILPAMED"
bse_code: "530549"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
market_cap_cr: 18124.57
generated_at: "2026-09-13T18:35:38.493Z"
---

# Shilpa Medicare Ltd (SHILPAMED)

Canonical page: https://tapetide.com/stocks/SHILPAMED

## Company

- **NSE Symbol:** SHILPAMED
- **BSE Code:** 530549
- **ISIN:** INE790G01031
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2009-12-03
- **CEO:** Mr. Vishnukanth Chaturbhuj Bhutada B. Pharm
- **Employees:** 998
- **Face Value:** ₹1
- **F&O Eligible:** No
- **Website:** vbshilpa.com

## About

Shilpa Medicare Incorporated in 1987 manufactures niche APIs, intermediates, and formulations and also undertakes contract research and manufacturing service for some of its customers. The company’s formulation products consist of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SML’s wholly owned subsidiary Shilpa Therapeutics.[1]

## Latest Price

- **Price:** ₹961.15
- **Change:** +21.25 (+2.26%)
- **Open:** ₹935
- **Day High:** ₹975
- **Day Low:** ₹910
- **Previous Close:** ₹939.9
- **Volume:** 1471659
- **As Of:** 2026-09-11T10:22:35+00:00

## Key Fundamentals

Observed at 2026-09-11T04:36:21.538908Z.

- **Market Cap:** ₹18124.57 Cr
- **Classification:** Smallcap
- **P/E (reported):** 61.9
- **P/E (TTM):** 63.23
- **EPS (TTM):** ₹15.2
- **Book Value:** ₹132.49
- **Price to Book:** 7.1
- **Dividend Yield:** 0.06%
- **ROE:** 9.39%
- **ROCE:** 12.39%
- **Debt to Equity:** 0.25
- **Revenue (yearly):** ₹1548.7 Cr
- **Net Income:** ₹243.3 Cr
- **EBITDA:** ₹444.5 Cr
- **52-Week High:** ₹980.1
- **52-Week Low:** ₹259.5
- **RSI (14):** 66.12

## Tapetide Score

- **Score:** 46 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Rising
- **Percentile:** 31.9 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 45.75 | 9% |
| growth | 76.2 | 9% |
| momentum | 98.9 | 12% |
| ownership | 46.4 | 24% |
| quality | 36.51 | 22% |
| valuation | 29.42 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is expected to give good quarter

### Weaknesses

- Stock is trading at 7.25 times its book value
- The company has delivered a poor sales growth of 11.3% over past five years.
- Company has a low return on equity of 5.39% over last 3 years.
- Promoter holding has decreased over last 3 years: -9.88%

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 158.7% | 150.37% | 225.48% |
| ebitda margin growth | -11.72% | 9.67% | 31.71% | 52.58% |
| net income growth | -6.4% | 210.73% | 107% | 17% |
| revenue growth | -1.47% | 18.24% | 14% | 11% |
| roce | -17.85% | 65.2% | 103.45% | 6.66% |
| roe | -6.41% | 183.69% | 4.83% | 181.14% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 313 | 287 | 292 | 293 | 344 | 319 | 331 | 321 | 370 | 410 | 437 | 466 |
| Expenses | 255 | 222 | 222 | 222 | 258 | 239 | 252 | 231 | 262 | 296 | 317 | 330 |
| Operating Profit | 58 | 65 | 70 | 70 | 86 | 81 | 79 | 91 | 108 | 114 | 120 | 136 |
| OPM % | 19 | 23 | 24 | 24 | 25 | 25 | 24 | 28 | 29 | 28 | 27 | 29 |
| Other Income | 2 | 2 | 9 | 10 | 5 | 2 | -21 | 6 | 2 | -13 | 45 | 9 |
| Interest | 23 | 26 | 24 | 24 | 26 | 12 | 14 | 19 | 16 | 11 | 14 | 12 |
| Depreciation | 28 | 27 | 27 | 27 | 28 | 29 | 29 | 29 | 30 | 30 | 31 | 35 |
| Profit before tax | 9 | 14 | 28 | 29 | 37 | 42 | 15 | 50 | 64 | 61 | 120 | 98 |
| Tax % | 83 | 67 | 12 | 51 | 51 | 24 | 5 | 5 | 32 | 27 | 10 | -3 |
| Net Profit | 2 | 5 | 24 | 14 | 18 | 32 | 15 | 47 | 44 | 45 | 108 | 101 |
| EPS in Rs | 0.09 | 0.26 | 1.41 | 0.72 | 0.92 | 1.62 | 0.74 | 2.4 | 2.25 | 2.28 | 5.51 | 5.16 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 789 | 733 | 908 | 899 | 1141 | 1046 | 1146 | 1281 | 1535 | 1683 |
| Expenses | 634 | 585 | 688 | 718 | 940 | 947 | 907 | 962 | 1100 | 1204 |
| Operating Profit | 155 | 148 | 219 | 181 | 202 | 99 | 239 | 319 | 435 | 479 |
| OPM % | 20 | 20 | 24 | 20 | 18 | 9 | 21 | 25 | 28 | 28 |
| Other Income | 22 | 33 | 17 | 90 | 21 | 17 | 15 | -8 | 39 | 43 |
| Interest | 3 | 4 | 5 | 22 | 41 | 59 | 92 | 76 | 59 | 52 |
| Depreciation | 37 | 42 | 44 | 54 | 80 | 96 | 108 | 113 | 120 | 126 |
| Profit before tax | 137 | 136 | 188 | 195 | 102 | -38 | 54 | 122 | 295 | 344 |
| Tax % | 25 | 19 | 18 | 25 | 41 | -19 | 41 | 36 | 18 | — |
| Net Profit | 103 | 110 | 155 | 146 | 61 | -31 | 32 | 78 | 243 | 297 |
| EPS in Rs | 6.45 | 6.88 | 9.57 | 9.06 | 3.49 | -1.87 | 1.84 | 4 | 12.44 | 15.2 |
| Dividend Payout % | 5 | 7 | 6 | 6 | 16 | 0 | 0 | 12 | 5 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | 20 |
| Reserves | 979 | 1077 | 1189 | 1321 | 1471 | 1814 | 1775 | 1800 | 2353 | 2572 |
| Borrowings | 241 | 191 | 194 | 390 | 846 | 683 | 798 | 937 | 588 | 660 |
| Other Liabilities | 244 | 223 | 218 | 270 | 308 | 370 | 323 | 347 | 360 | 455 |
| Total Liabilities | 1472 | 1499 | 1610 | 1989 | 2632 | 2876 | 2904 | 3093 | 3311 | 3706 |
| Fixed Assets | 492 | 534 | 558 | 650 | 1111 | 1342 | 1368 | 1385 | 1418 | 1593 |
| CWIP | 141 | 210 | 429 | 666 | 541 | 506 | 655 | 719 | 822 | 884 |
| Investments | 253 | 140 | 2 | 10 | 21 | 34 | 43 | 40 | 35 | 58 |
| Other Assets | 587 | 615 | 621 | 662 | 959 | 993 | 838 | 950 | 1037 | 1170 |
| Total Assets | 1472 | 1499 | 1610 | 1989 | 2632 | 2876 | 2904 | 3093 | 3311 | 3706 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 37 | 45 | 147 | 124 | 47 | 105 | 180 | 137 | 132 | 342 |
| Cash from Investing Activity | -257 | -10 | -196 | -290 | -404 | -286 | -232 | -171 | -198 | -339 |
| Cash from Financing Activity | 313 | -61 | 10 | 176 | 436 | 83 | 46 | 47 | 63 | 14 |
| Net Cash Flow | 93 | -26 | -39 | 10 | 79 | -98 | -7 | 13 | -3 | 17 |
| Free Cash Flow | -79 | -92 | -151 | -220 | -302 | -226 | -46 | -48 | -111 | -28 |
| CFO/OP | 43 | 55 | 123 | 76 | 52 | 69 | 215 | 74 | 56 | 93 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 80 | 102 | 101 | 99 | 88 | 124 | 113 | 125 | 126 | 123 |
| Inventory Days | 187 | 194 | 266 | 298 | 427 | 338 | 280 | 309 | 309 | 291 |
| Days Payable | 110 | 106 | 115 | 122 | 91 | 139 | 125 | 156 | 93 | 113 |
| Cash Conversion Cycle | 157 | 189 | 253 | 275 | 425 | 323 | 268 | 278 | 342 | 301 |
| Working Capital Days | 79 | 98 | 98 | 68 | 72 | 77 | -13 | 48 | 80 | 51 |
| ROCE % | 14 | 10 | 9 | 12 | 8 | 6 | 1 | 5 | 8 | 11 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 50.01% | 50.01% | 50.01% | 44.39% | 44.33% | 44.23% | 44.23% | 44.23% | 44.23% | 40.13% | 40.13% | 40.13% |
| FIIs | 8.6% | 8.52% | 5.63% | 9.08% | 9.58% | 9.9% | 10.97% | 11.2% | 10.92% | 10.97% | 11.08% | 11.38% |
| DIIs | 0.41% | 0.06% | 1.59% | 7.61% | 8.18% | 8.27% | 7.55% | 7.46% | 7.67% | 8.33% | 8.58% | 8.05% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 25.4% | 25.45% | 27.64% | 24.69% | 23.94% | 24.4% | 24.43% | 23.21% | 23.34% | 27.8% | 27.7% | 27.67% |
| Others | 15.59% | 15.96% | 15.12% | 14.23% | 13.96% | 13.21% | 12.83% | 13.9% | 13.84% | 12.76% | 12.51% | 12.76% |
| No. of Shareholders | 44094 | 43630 | 44793 | 41072 | 42784 | 49034 | 50108 | 48636 | 52065 | 53799 | 53410 | 60926 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 13 / 3 / 3

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 944.89 | Buy |
| EMA (10) | 936.62 | Buy |
| SMA (20) | 894.77 | Buy |
| EMA (20) | 894.12 | Buy |
| SMA (50) | 755.56 | Buy |
| EMA (50) | 783.45 | Buy |
| SMA (100) | 628.25 | Buy |
| EMA (100) | 668.41 | Buy |
| SMA (200) | 479.47 | Buy |
| EMA (200) | 556.56 | Buy |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 68.71 | Neutral |
| MACD (12,26,9) | 60.19 | Sell |
| Stochastic (14,3,3) | 83.87 | Sell |
| ADX (14) | 59.77 | Buy |
| Williams %R (14) | -13.11 | Sell |
| ATR (14) | 39.14 | High Volatility |
| ROC (12) | 11.66 | Buy |
| Stoch RSI (14) | 12.7 | Buy |
| UO (7,14,28) | 57.96 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 3 | 75% |
| Hold | 1 | 25% |
| Sell | 0 | 0% |

Based on 4 analyst ratings, observed at 2026-09-11T04:36:21.529440+00:00.

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 Apr - Shilpa Medicare says it does not qualify as a Large Corporate under SEBI norms. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 9 Apr - Shilpa Medicare says it does not qualify as a Large Corporate under SEBI norms.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d09c43d6-9193-477c-b646-ab644f8ae423.pdf) |
| 6 Apr - Submission of confirmation certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31 March 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Apr - Submission of confirmation certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b76ec48e-8db1-4e04-8aab-9e40b0bc4367.pdf) |
| 5 Mar - NCLT approved amalgamation of Shilpa Therapeutics into listed Shilpa Medicare; effective after certified order and ROC filing. | [Announcement under Regulation 30 (LODR)-Scheme of Arrangement 5 Mar - NCLT approved amalgamation of Shilpa Therapeutics into listed Shilpa Medicare; effective after certified order and ROC filing.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/042dcea3-f9cf-4676-98bb-b1add94a589c.pdf) |
| 3m - Appointment of Dr. Vellaian Karuppiah as Chief Operating Officer (COO)- Formulations - Senior Managerial Personnel. | [Announcement under Regulation 30 (LODR)-Change in Management 3m - Appointment of Dr. Vellaian Karuppiah as Chief Operating Officer (COO)- Formulations - Senior Managerial Personnel.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/f4749f81-b8d9-45fb-b09c-368a870bacad.pdf) |
| 25 Mar - Trading window closed from 1 April 2026 until 48 hours after board approval of audited FY2026 results. | [Closure of Trading Window 25 Mar - Trading window closed from 1 April 2026 until 48 hours after board approval of audited FY2026 results.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d19924a7-3b2b-453c-a050-c355145d7a56.pdf) |
| 24 Feb - 24 Feb 2026: Shilpa Biologicals licenses biosimilar to SteinCares for exclusive commercialization across Latin America; Dharwad manufacturing. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 24 Feb - 24 Feb 2026: Shilpa Biologicals licenses biosimilar to SteinCares for exclusive commercialization across Latin America; Dharwad manufacturing.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/14e79a01-5772-45cd-91a9-8596e209f702.pdf) |
| 23 Apr - Dr. Vellaian Karuppiah appointed COO-Formulations effective 23 April 2026. | [Announcement under Regulation 30 (LODR)-Change in Management 23 Apr - Dr. Vellaian Karuppiah appointed COO-Formulations effective 23 April 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f4749f81-b8d9-45fb-b09c-368a870bacad.pdf) |
| 22 Apr - Dr. Jayant Karajgi retired as COO-Formulations and SMP, effective 22 April 2026. | [Announcement under Regulation 30 (LODR)-Change in Management 22 Apr - Dr. Jayant Karajgi retired as COO-Formulations and SMP, effective 22 April 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2495fb02-89cc-4243-9168-4dc9ff4485fc.pdf) |
| 19 Feb - Newspaper advertisement - Special Window for Transfer and Dematerialisation of Physical shares. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 19 Feb - Newspaper advertisement - Special Window for Transfer and Dematerialisation of Physical shares.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cfc5d7e2-fd96-4352-a789-2adedfeccd94.pdf) |
| 17 Mar - NCLT approved amalgamation; certified order received 16 Mar 2026; appointed date 1 Apr 2025. | [Announcement under Regulation 30 (LODR)-Scheme of Arrangement 17 Mar - NCLT approved amalgamation; certified order received 16 Mar 2026; appointed date 1 Apr 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2adaa99b-1ec7-4aa1-9c3d-aa934e8e7c35.pdf) |

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-10 | [Initiation Of NCLT Order On FTF Pharma Private Limited A Wholly Owned Subsidiary Of Shilpa Medicare Limited.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=82950c2a-0719-4044-a010-1f1cd0c456e1.pdf) |
| 2026-08-19 | [Dispatch Of Letter To Shareholders Whose E-Mail Addresses Are Not Registered With Company/Registrar & Transfer Agent /Depository Participants](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=88916278-cb08-467c-a44d-5cf2c04e1f0f.pdf) |
| 2026-08-18 | [Response On The News Item Captioned Shilpa Medicare Recalls Over 27K Vials Of Chemotherapy Drug In US Published In The Online Edition Of The Economic Times On August 17 2026 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2faafad5-1f1e-41e0-8e06-e1cca71f0fca.pdf) |
| 2026-08-17 | [Announcement under Regulation 30 (LODR)-Dividend Updates](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cf68c362-4be8-44be-8782-f2c7dda63a3e.pdf) |
| 2026-08-14 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ab0f3961-d4a4-476e-bd09-738012bcbfc5.pdf) |
| 2026-08-13 | [39Th Annual General Meeting Notice](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7f87e847-1d74-4259-9271-4c513d4792ca.pdf) |
| 2026-08-13 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a1cd6b7a-c662-4674-9f54-965eeb8b1cdd.pdf) |
| 2026-08-05 | [Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended 30 June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=be0665fa-c28b-494a-800c-58701750f784.pdf) |
| 2026-08-05 | [Final Dividend For The FY 2025-26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a39722b2-f67f-4301-920f-2288dc5619c1.pdf) |
| 2026-08-05 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0dd0008b-9cff-4ae9-a2c4-46ccf12794c4.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-10 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac53a44d-9e05-41a9-8678-5ccfba1b8efb.pdf) |
| 2026-05-26 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=33c87f15-3d6d-4a67-a887-1f40772259bf.pdf) |
| 2026-02-10 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=02000b11-4874-47b7-9bce-a436bddb4971.pdf) |
| 2025-11-19 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=00621fce-9a08-4b3c-95f2-056191f3f1e6.pdf) |
| 2025-08-18 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5ecb9de7-f789-4f36-89e1-47ec2bae2173.pdf) |
| 2025-02-14 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c4ff9677-1853-4214-bb2d-342d1f9911d7.pdf) |
| 2024-11-20 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=473d0784-ca83-47df-934b-93e1d709096d.pdf) |
| 2024-08-13 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c7c82758-1598-4a4d-b49b-a443fa32621f.pdf) |
| 2024-07-12 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ad8817e8-3d00-48ab-9564-421eada17a7c.pdf) |
| 2024-05-28 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ccdeedf1-a2d7-491e-8649-b667701d15b0.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-05 | [Unaudited Standalone And Consolidated Financial Results For The Quarter Ended 30 June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8e8e871c-f078-4894-9f9c-0be3ae7e1ec6.pdf) |
| 2026-05-22 | [Financial Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c2df9d1c-b2b2-4638-899c-554b37b015ca.pdf) |
| 2026-02-06 | [Announcement Under Regulation 30 (LODR)-Meeting Updates](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=75ec2217-3895-4f70-b75a-e2c048839281.pdf) |
| 2025-11-13 | [Outcome Of The Board Meeting Of The Company Held On 13 November 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dd8b1ddb-e229-4725-81d9-5526fa85fae2.pdf) |
| 2025-08-13 | [Results - Financial Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=839414b9-0042-4bfb-869f-04887a1d85fb.pdf) |
| 2025-05-26 | [Results - Financial Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=80ccd234-cb55-4109-8836-a5b99bceeecd.pdf) |
| 2025-05-26 | [Board Meeting Outcome Financial Results For The Quarter And Year Ended 31 March 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a87fa1be-248b-4176-be57-b9701a1bedb9.pdf) |
| 2025-02-10 | [Unaudited Financial Results For The Quarter Ended 31St December 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=129f2a93-38fa-4179-822b-370521eb7569.pdf) |
| 2024-11-13 | [The Un-Audited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended 30September 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5a798b55-3524-431c-a39e-c5d098f81359.pdf) |
| 2024-08-08 | [Unaudited Financial Results For The Quarter Ended 30Th June, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=30571032-2c5c-4779-80bf-e029ec9b0bf8.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-05 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fab43b0e-31f7-4565-8197-60d8aa5dba4a.pdf) |
| 2026-05-22 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d8fbdf4d-cadc-4d71-b78c-359c6dc287ea.pdf) |
| 2026-02-06 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0f646961-62a0-4a72-b502-e3540ce604b9.pdf) |
| 2025-11-13 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a03c30ef-9c94-4dc3-bb28-276237ee82e1.pdf) |
| 2025-08-13 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dd699d43-b02c-49b7-a8ba-9fad8f28b415.pdf) |
| 2025-05-26 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=50ae8588-040b-4546-a0d1-e8c970eadd04.pdf) |
| 2025-02-10 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=74cee299-e9e1-4059-aaf8-d08fa8b25c55.pdf) |
| 2025-02-10 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f7b8099b-2683-49d5-8ce3-cfec419b30d8.pdf) |
| 2024-11-13 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4b3446c9-bf71-41df-892b-87db0e960568.pdf) |
| 2024-08-08 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3ee85616-1f35-409c-bf13-3a7843cf5753.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Oct 2021 | [Concall - Oct 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3e6e95e8-f550-4324-acd5-1ef3cc451de6.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/00621fce-9a08-4b3c-95f2-056191f3f1e6.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/473d0784-ca83-47df-934b-93e1d709096d.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f2e304e1-8071-41df-a179-84ce6188d00f.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bc3b23e4-3f8d-4aae-8845-10b1c0d0a442.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2bb8ccbb-2077-49db-9258-f5a7f4f0b211.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bc3b23e4-3f8d-4aae-8845-10b1c0d0a442.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2bb8ccbb-2077-49db-9258-f5a7f4f0b211.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/33c87f15-3d6d-4a67-a887-1f40772259bf.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/33c87f15-3d6d-4a67-a887-1f40772259bf.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a1cd6b7a-c662-4674-9f54-965eeb8b1cdd.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b8189cb5-7760-4799-b1fc-2198d8f48180.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7d59d30c-8efc-48bd-966f-262d76b0ca2e.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1ac57c99-5517-4291-84c1-8fe9d6b579f3.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/530549/76191530549.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2025-05-26 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=36e92da8-cf88-420c-8778-166de455ea17.pdf) |
| 2024-11-14 | [Analysts/Investors Call - Call Recording](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=20a35181-d758-4a7f-a238-f1528676a5c8.pdf) |
| 2024-08-09 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7bd38829-dc64-4bbe-a139-b7f6a655aa7c.pdf) |
| 2024-07-08 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ec35ad4a-588e-4eaf-8012-c685a9ca52c7.pdf) |
| 2024-05-24 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f31e53eb-b2d2-455b-ba14-703eeaff8330.pdf) |
| 2024-02-15 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ab25d850-693e-4ff0-a402-4fa83ad934d9.pdf) |
| 2023-11-11 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ad26dfc8-5d3c-4eee-8253-79f8e6d6d326.pdf) |
| 2023-05-27 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=86d4c13e-d8b9-4cf5-a54a-b39b240264db.pdf) |
| 2023-02-16 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8fcd1242-b748-4636-93d6-38dad9d4bf8f.pdf) |
| 2022-11-14 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=15f3e9b4-1c8b-4edf-bc70-9cc4ccf4655e.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:35:38.493Z.